CD25 has become widely used as a marker for a subset of regulatory CD4 + T cells present in the thymus and periphery of mice, rats and humans. However, CD25 is also expressed on conventionally activated T cells that are not regulatory and not all peripheral regulatory T cells express CD25. The identi®cation of a stable and unique marker for regulatory T cells would therefore be valuable. This study provides a detailed account of the phenotype of CD4 + CD25 + regulatory T cells in rats. In the thymus, CD4 + CD8 ± CD25 + cells were found to have a more mature phenotype than the corresponding CD4 + CD8 ± CD25 ± cells with respect to expression of Thy1 (CD90), CD53 and CD44, suggesting that CD25 expression, and perhaps commitment to regulatory function, might be a late event in thymocyte development. CD4 + CD25 + cells in both the thymus and periphery were found to have enriched and heterogeneous expression of activation markers such as OX40 (CD134) and OX48 (an antibody determined in this study to be speci®c for CD86). CD4 + CD25 + T cells were also found to have enriched expression of CD80, at both the mRNA and protein level. However, functional studies in vitro and in vivo showed that neither OX40 or CD86 were useful markers for the further subdivision of regulatory T cells. Our studies indicate that, at present, CD25 remains the most useful marker to enrich for regulatory CD4 + T cells in rats and no further subdivision of the regulatory component of CD4 + CD25 ± CD45RC low T cells has yet been achieved.
Introduction
Evidence has accumulated in recent years for the existence of regulatory CD4 + T cells that have immune suppressive activity and play a role in maintaining immunological tolerance. In particular, regulatory T cell activity has been shown to be enriched in a minority subset of CD4 + T cells that express CD25, and are found in both the thymus and periphery of mice, rats and humans (1, 2) . The range of disease states which cells of this phenotype have now been shown to regulate is wide and includes organ-speci®c autoimmune disease (including gastritis, thyroiditis and insulin-dependent diabetes) (3±7), in¯ammatory bowel disease (8) , in¯ammatory lung disease (9) , allograft rejection (10±12), graft versus host disease (13±15), allergy (16) , sterilizing immunity to infectious organisms such as Leishmania major (17) , and, less bene®-cially, CD4 + CD25 + cells also hinder tumour immunity (18) . CD4 + CD25 + T cells also have immune suppressive activity in vitro, and can suppress the proliferation and cytokine production of other T cells, both CD4 + and CD8 + , via an as yet unde®ned cell-contact dependent mechanism (19, 20) . However, CD4 + CD25 + T cells act not only on T cells, but have also been shown to regulate cells of the innate immune system, as demonstrated by their ability to prevent Helicobacter hepaticus-triggered colitis in T cell-de®cient mice (21) .
Although there are now many studies that show an important role for CD4 + CD25 + T cells in tolerance, many aspects of their biology remain unclear, including precise details regarding their development, speci®city and mechanism of action. Another problem that hinders studies of regulatory T cells, particularly in humans, is the lack of a unique marker that de®nes all cells with regulatory activity, as CD25 has a number of limitations in this regard. As a molecule that is induced on all T cells after activation, CD25 cannot distinguish regulatory T cells from conventional activated T cells which also express CD25. Another limitation is that CD25 is not expressed on all CD4 + T cells with regulatory activity. Although regulatory T cells in both the thymus and periphery are enriched in the CD4 + CD25 + T cell subset, in the periphery of rodents there is evidence also for regulatory CD4 + CD25 ± T cells present within the memory CD45RC low subset in rats (CD45RB low in mice) (6, 7, 12, 16, 22) . The relationship between the CD25 + and CD25 ± regulatory cells in the periphery has not yet been established, and could either be the result of instability of this marker on a single regulatory T cell subset or due to the existence of different lineages of regulatory cells that perhaps even have separate mechanisms of action.
It is clear, therefore, that one important goal of research in the regulatory T cell ®eld is the better de®nition of the phenotype of these cells and a search for markers that more speci®cally label only those cells with regulatory activity. With this aim in mind, we have phenotypically characterized CD4 + CD25 + T cells from the thymus, blood, spleen and lymph nodes of rats using the currently available antibodies in this species, and have tested the subsets of CD25 + T cells so identi®ed for their regulatory capacity in vitro and in vivo.
Methods

Antibodies
The following mouse anti-rat IgG1 antibodies used in these experiments were supernatants produced from hybridomas in the Sir William Dunn School of Pathology, Oxford, by Mike Puklavec:
, 2G7 (IgG2a, antihuman TGFb, cross-reactive with rat) (25) and 10/78 [anti-NKR-P1A (CD161a)]. OX21 (mouse IgG1, reactive with human Factor I) was used as an isotype control antibody. Some of these antibodies were puri®ed and biotinylated using standard methods. Cy5-conjugated W3/25 and R73 (conjugated by Ulf Yrlid, Sir William Dunn School of Pathology, Oxford) were also used in some experiments. 3H5 [anti-rat B7-1 (CD80)] and 24F [anti-rat-B7-2 (CD86)] were used as puri®ed antibodies. References for all of these antibodies, unless given above, can be found in (26) . Anti-rat OX40± phycoerythrin (PE), anti-rat CD25±FITC and¯uorescein-conjugated isotype control mAb were obtained from Serotec (Oxford, UK). PE-conjugated rat-adsorbed donkey anti-mouse IgG F(ab¢) 2 (DAM±PE) (Jackson Laboratories, West Grove, PA) was used for the detection of unconjugated mouse mAb and streptavidin±Quantum Red (Sigma, St Louis, MO) to detect staining of biotinylated antibodies.
Flow cytometry
For¯ow cytometric analysis, cells were stained with appropriately diluted antibody for 30 min on ice, washed twice with PBS/2% FCS and analysed on a FACSCalibur (Becton Dickinson, Oxford, UK) using CellQuest software (Becton Dickinson). For triple-colour analysis, cells were incubated ®rst with the unconjugated mAb, washed, and detected with DAM± PE. After 20 min blocking with 5% normal mouse serum in PBS, the cells were then co-incubated with the FITC-and biotinconjugated antibodies, washed, and incubated for a further 30 min with streptavidin±Quantum Red.
Puri®cation of T cell subsets
Donor peripheral cells were obtained from pooled single-cell suspensions of cervical and mesenteric lymph nodes and spleen (after lysis of red blood cells) of 8-to 16-week-old female PVG.RT1 u rats. Enrichment for CD4 + cells involved incubation for 40±50 min on ice with the mouse mAb OX7, OX8, OX12 or OX33, OX42 and 10/78, followed by washing and two consecutive rounds of depletion with goat anti-mouse IgG-coated M450 magnetic beads (Dynal, Oslo, Norway). The ef®ciency of the depletion was con®rmed by labelling cells pre-and post-depletion with DAM±PE for 20 min for¯ow cytometric analysis and the percentage of contaminating cells was consistently <2%, with CD4 + T cell enrichment of 84±91%. Enrichment of CD4 + CD8 ± thymocytes was performed by negative selection of CD8 + thymocytes from 5-to 12-weekold female PVG.RT1 u rats, by rosette depletion with OX8-coated sheep red blood cells (27) . The resulting population of cells typically contained 80% single-positive CD4 + CD8 ± thymocytes and 20% CD4 ± CD8 ± thymocytes, and <2% contaminating CD8 + cells. For in vivo experiments, fractionation of the enriched CD4 + T cells on the basis of CD25 expression and a second marker was then performed by staining cells with FITC-and PE-labelled antibodies, followed by separation with FITC±multisort magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) used according to the manufacturer's instructions and then further separation with anti±PE magnetic beads (Miltenyi Biotec). For in vitro experiments requiring fewer cells, the enriched CD4 + T cells were stained as above and sorted on a MoFlo high-speed cell sorter (DakoCytomation; Dako, Ely, UK). In both cases, the purity of the fractionated cells after sorting was analysed on the¯ow cytometer and the percentage of CD4 + cells in each subset determined.
Induction and monitoring of insulin-dependent diabetes mellitus in PVG.RT1 u rats PVG.RT1 u rats were bred and housed in speci®c pathogenfree conditions at the Sir William Dunn School of Pathology, Oxford. Insulin-dependent diabetes mellitus was induced in female PVG.RT1 u rats by a protocol involving thymectomy at 6 weeks of age, followed by four doses of 250-rad g-irradiation at 2-week intervals, beginning 2 weeks after thymectomy, and described in more detail elsewhere (28, 29 ). Cells to be tested for regulatory activity were injected i.v. shortly after the last irradiation. The cell dose was chosen on the basis of the known number of CD4 + CD25 + or CD4 + CD25 ± CD45RC low cells required to give protection (6) . Animals were subsequently weighed twice weekly for at least 12 weeks and those exhibiting weight loss were tested for the development of diabetes, as assessed by measurement of blood glucose levels using Glucostix (Bayer Diagnostics, Newburgh, UK) and con®rmed by the presence of glycosuria with Clinistix (Bayer Diagnostics). Animals were considered diabetic if their blood glucose levels were >16 mM and they also tested positive for glycosuria. The onset of diabetes in control animals occurred 5±8 weeks after the last irradiation.
In vitro proliferation assays
Cells were cultured in triplicate in U-bottomed 96-well plates in RPMI supplemented with 10% heat-inactivated FCS, 50 IU/ml penicillin, 50 mg/ml streptomycin, 2 mM glutamine, 1 mM sodium pyruvate and 25 mM 2-mercaptoethanol. Responder T cells were added at 10 5 cells per well, with 10 5 g-irradiated (3000 rad) mixture of spleen and lymph node cells as a source of antigen-presenting cells (APC). In co-culture experiments, increasing numbers of CD25 + cells were titrated into wells with the ®xed dose of CD25 ± cells indicated above. Cells were stimulated with 2.5 mg/ml concanavalin A. Cells were pulsed at 72 h with 0.5 mCi [ 3 H]thymidine and cultured a further 18 h before harvesting onto glass ®bre ®lter mats and counting. Results shown are the mean T SD of triplicate wells.
Immunoprecipitation and protein sequencing
OX48 antibody (puri®ed on a Protein G column by FPLC) was covalently coupled to CNBr-4B Sepharose (Pharmacia) as recommended by the manufacturer. OX48-coupled Sepharose beads were then mixed with pre-cleared sodium deoxycholate-solubilized rat spleen lysates [prepared as described in (30) ] and rotated overnight at 4°C. The Sepharose beads were then pelleted by centrifugation, washed in deoxycholate buffer and the protein eluted in 0.5% SDS at 55°C. The eluted material was concentrated using spin concentrators (Amicon) and loaded onto a NuPage 4±12% Bis-Tris minigel (Invitrogen) under non-reducing conditions. The major band of~70-kDa on SDS±PAGE was digested with trypsin, and then peptides were separated and sequenced by automated Edman degradation in a PerkinElmer Procise 494A protein sequencer (Applied Biosystems).
RNA extraction and RT-PCR
Total RNA was isolated from 10 6 FACS-sorted CD25 + or CD25 ± CD8 ± TCRab + rat thymocytes using Tri Reagent (Sigma) according to the manufacturer's instructions. Positive control RNA was puri®ed from p815 cells transfected with rat CD80 or CD86 and negative control RNA was puri®ed from untransfected p815 cells (all kindly provided by Hideo Yagita, Tokyo, Japan). mRNA was reverse transcribed using SuperScriptII RNase H ± reverse transcriptase (Gibco/BRL, Life Technologies, Paisley, UK) according to the manufacturer's instructions in a 20 ml reaction volume. Reverse transcriptasenegative control reactions (RT ± ) were prepared using equivalent amounts of RNA in water. PCR reactions were performed with 1 ml of cDNA or RT ± in a 20 ml reaction mix containing 2 ml 10 Q PCR Buffer (Clontech), 0.6 ml dNTPs each at 10 mM (Sigma), 2 ml each of forward and reverse primers (10 mM; synthesized by Sigma-Genosys), and 0.5 ml Taq DNA polymerase (Clontech). The primer sequences used were: sense 5¢-CTG CTG CTG GTT GGT CTA TTC-3¢ and antisense 5¢-GTG GTC GTA CGT CGT GTT GA-3¢ to amplify a 573-bp fragment of rat CD80, and sense 5¢-AAA CAT AAG CCC GAG TGA GC-3¢ and antisense 5¢-TGC AAT CTG GAT CCA AGT CT-3¢ to amplify a 607-bp fragment of rat CD86. b-Actin was used as an internal control for RT-PCR and to normalize cDNA concentration in the samples, and the primers used were: sense 5¢-ATG CCA TCC TGC GTC TGG ACC TGG-3¢ and antisense 5¢-AGC ATT TGC GGT GCA CGA TGG AGG G-3¢. Reactions were performed in a PTC-0225 DNA Engine Tetrad (MJ Research). The PCR reaction was ®rst subjected to a denaturation step at 94°C for 2 min, followed by cycles of 30 s annealing at 62°C, 45 s of elongation at 72°C and 30 s of denaturation at 94°C. In total, 34 cycles were performed for CD80 and CD86 reactions and 24 cycles for b-actin. PCR fragments were visualized by electrophoresis on a 1% agarose gel containing ethidium bromide and images were recorded using GeneSnap Version 4.00.00 (Syngene, Cambridge, UK).
Results
Phenotypic analysis of rat CD4 + CD25 + T cells in the thymus and periphery
CD4 + T cells from the thymus, lymph nodes, spleen and blood of rats were screened ex vivo with an extensive panel of antibodies reactive with rat lymphocyte cell-surface molecules to search for markers that are differentially expressed on CD25 + and CD25 ± T cells. Both CD25 + and CD25 ± subsets of CD4 + CD8 ± thymocytes and peripheral CD4 + T cells were found to have equivalent uniformly positive expression of the following markers: TCRab, CD2, CD5, CD6, CD26, CD28, CD43 (as detected by OX56), CD45, CD147 and MHC class II (this last marker only being present on a minority subset of peripheral T cells, but weakly expressed on most CD4 + CD8 ± thymocytes); and lacked detectable cell-surface expression of TCRgd, NKR-P1A, CD71 (transferrin receptor), transforming growth factor-b and OX62 (data not shown). Differences in the phenotype of the two subsets were found with respect to the markers shown in Fig. 1 . There were no differences between spleen and lymph node cells with respect to any of the markers examined, and the phenotype of cells in blood was also identical to that of spleen and lymph nodes, with the only difference being that, as already described for thoracic duct lymphocytes (6), there was a slightly lower percentage of CD25 + cells in blood compared with spleen and lymph nodes.
The most striking phenotypic differences in CD25 + compared with CD25 ± CD4 + T cells in both the thymus and the periphery were found with respect to expression of OX40 (CD134), OX48, CD80 (B7-1) and CD86 (B7-2). CD25 + cells had a greatly increased proportion of cells staining positively for each of these markers compared to mostly negative expression on CD25 ± cells. These markers were therefore chosen to study further as potential candidates for further functional subdivision of regulatory T cells. Some phenotypic differences were found between CD25 + and CD25 ± cells in the thymus, but not in the periphery, and were therefore considered to indicate different maturational states of the two subsets in the thymus. In the thymus, CD25 + cells were predominantly CD44 hi CD53 hi Thy1 lo and thus had a more mature phenotype than CD25 ± thymocytes, with closer resemblance to the phenotype of peripheral T cells (Fig. 1) . In the periphery, however, the difference in the levels of expression of these molecules on CD25 + and CD25 ± cells was minimal, with most CD4 + peripheral cells appearing CD44 hi CD53 hi CD90(Thy1) ±/low , although consistently there was detection of slightly higher expression of CD44 on peripheral CD25 + cells compared with CD25 ± cells (Fig. 1 ).
There were other more subtle differences in the expression of certain markers on CD25 + compared with CD25 ± cells, both in the thymus and periphery. CD25 + cells had slightly higher levels of expression of MHC class I, CD48 and CD54 (ICAM) in comparison to CD25 ± cells. CD200 (OX2) was expressed on all CD4 + CD8 ± thymocytes with marginally lower levels on CD25 + versus CD25 ± thymocytes, but was expressed on a higher percentage of CD25 + cells in the periphery. LFA-1 was expressed in higher levels by CD25 + cells in the periphery, although there was no differential expression of this marker on thymocytes. CD62L expression was similar for CD25 + and CD25 ± thymocytes, but the percentage of CD62L low cells was slightly increased in the peripheral CD25 + subset. As described previously, CD25 + cells have mostly low to intermediate expression of CD45RC in the periphery (6) . There was also a small proportion (~16%) of peripheral CD4 + CD25 + cells expressing CD8. The regulatory potential of this subset is unknown, as previous experiments on regulatory T cells in rats have been done with CD4 + cells that were negatively selected using anti-CD8 antibodies (6) . In addition, there was differential expression with respect to the isoform of CD43 recognized by the antibody W3/13, although both subsets had uniform high expression of CD43 when stained with another antibody OX56. CD25 + cells had an increased proportion of W3/13 low cells compared with CD25 ± cells, both in the thymus and periphery. The W3/13 antibody is thought to be inhibited in its binding to highly glycosylated forms of CD43 (31).
OX40 expression does not functionally subdivide CD25 + or CD25 ± regulatory CD4 + T cells
It is known that the T cells from normal rats that can transfer protection from autoimmune diabetes to syngeneic lymphopenic recipients are enriched in the CD4 + CD25 + subset in both the thymus and periphery, but that additionally there is less potent regulatory activity present in the peripheral antigen-experienced CD4 + CD25 ± Thy1 ± CD45RC low T cell subset (6, 32) . OX40 was found to be expressed almost exclusively by CD45RC low cells in the periphery, and within this subset was expressed on~45% of CD25 + cells and~20% of CD25 ± cells (Fig. 2A) . OX40 is induced on T cells after activation and is thought to play a role in the survival of memory cells (33) . One hypothesis considered initially was that OX40 might be used as a marker to distinguish conventional activated T cells (co-expressing CD25 and OX40) from regulatory T cells (expressing CD25 and lacking OX40). Unexpectedly, however, OX40 was not found purely on peripheral T cells and there was great enrichment of OX40 expression on CD25 + thymocytes (Fig. 1) . In addition, a previously unrecognized observation was that, unlike most CD4 + T cells in the periphery, CD25 ± CD4 + CD8 ± thymocytes in rats express OX40, albeit at low levels (Fig. 1 ). An alternative hypothesis was that OX40 might be a better marker than CD25 for regulatory T cells.
We tested these various possibilities by subdividing CD4 + CD45RC low Thy1 ± peripheral T cells according to expression of both CD25 and OX40. The hallmark of regulatory T cells is their ability to inhibit autoimmune and in¯ammatory disease in vivo, and the fractionated T cell subsets were tested for their ability to protect thymectomized and irradiated (TxX) PVG.RT1 u rats from developing autoimmune diabetes. The results of a series of ®ve experiments are shown in Fig. 2(B) . Both the OX40 + and OX40 ± subsets of CD4 + CD25 + cells were able to prevent diabetes in TxX rats at the cell dose tested. Similarly, both OX40 + and OX40 ± subsets of CD4 + CD25 ± CD45RC low cells were capable of preventing diabetes at a higher cell dose, so OX40 expression was not capable of uniquely identifying those regulatory T cells present in the peripheral CD4 + CD25 ± T cell pool. The purities of cells used for in vivo experiments after MACS sorting are shown in Table 1 . The protection is not explained by the presence of contaminating cells, as the dose of contaminating cells is below that required to give protection in each case. Therefore, although OX40 expression was greatly enriched on cells with regulatory activity, it was not useful for their further functional subdivision within either the CD25 + or CD25 ± subsets.
Another useful correlate of the in vivo suppressive activity of regulatory CD4 + CD25 + T cells is their ability to suppress the proliferation of other T cells after co-culture in vitro. This has been reported previously for these cells in mice (19, 20) , humans (34±40) and, recently, also for rats (41) . As fewer cells were needed for the in vitro experiments, we were able to use FACS-sorted cells, yielding a higher degree of purity of the cell populations compared with those used for the in vivo assays (Fig. 3A) . Both OX40 + and OX40 ± subsets of CD25 + cells were hypoproliferative in the absence of exogenous IL-2, and suppressed the proliferation of both naive CD4 + CD25 ± OX40 ± CD45RC high and memory CD4 + CD25 ± OX40 ± CD45RC low/int cells during co-culture in vitro (Fig. 3B and C) . Although both subsets were suppressive, the in vitro assays revealed a slight increase in potency of the CD25 + OX40 + cells compared with the CD25 + OX40 ± cells in their suppressive activity (Fig. 3C) . With regard to CD25 ± CD45RC low cells, the OX40 + subset proliferated poorly compared with the OX40 ± subset in the absence of exogenous IL-2. However, in contrast to the CD25 + cells, neither subset of CD25 ± cells displayed the ability to suppress CD45RC high cells in vitro, although CD25 ± OX40 + marginally suppressed the proliferation of CD4 + CD25 ± OX40 ± CD45RC low/int cells (35% suppression at 1:1 ratio). CD25 ± OX40 + cells were also unable to suppress proliferation of whole CD4 + CD25 ± OX40 ± cells not fractionated according to CD45RC expression, even at a 1:1 ratio (data not shown); therefore, their ability to suppress T cell proliferation in vitro is at best extremely weak, despite their anergic phenotype. The ability of sorted CD4 + T cell subsets to protect against autoimmune diabetes. CD4 + T cells were enriched from the spleen and lymph nodes of PVG.RT1 u rats, and fractionated further with magnetic beads according to both CD25 and OX40 expression. In the experiments with CD25 ± OX40 ± CD45RC low cells, CD4 + cells were depleted of CD45RC high cells before CD25/OX40 sorting. The purity of the sorted subsets is indicated in Table 1 . Cell subsets were tested for their ability to transfer protection from autoimmune diabetes to syngeneic TxX recipients. The dose of cells injected (Q10 6 ) was: 0.7±1 CD25 + OX40 + , 0.7±1 CD25 + OX40 ± , 4 CD25 ± OX40 + , 4 CD25 ± OX40 ± CD45RC low and 20 CD45RC high . The results are pooled from a total of ®ve experiments. The phenotypes of the major contaminating cell populations are indicated in the right-hand column. Determination of the speci®city of OX48 mAb for rat CD86
The speci®city of the OX48 mAb, which had not been previously de®ned, was of particular interest due to its ability to subdivide CD4 + CD25 + T cells and its very low expression on CD4 + CD25 ± cells. Early studies using this antibody had found it to be reactive against a protein of~70 kDa found on a subset of activated T cells and dendritic cells (23) . In this study, ã 70-kDa molecule was immunoprecipitated from rat spleen lysates using OX48-coated Protein G±Sepharose beads (Fig. 4A) , digested into peptides, sequenced and compared to the sequence database. One of these peptides (SFDRDNQALR) was found to exactly match the sequence of rat B7-2 (CD86).
To con®rm the speci®city of OX48, rat CD86-transfected P815 cells (kindly provided by Hideo Yagita, Tokyo) were stained and analysed by¯ow cytometry. OX48 gave identical staining of CD86-transfected, but not wild-type or control CD80-transfected P815 cells, as the positive control mAb 24F (Fig. 4B) . OX48 did not appear to bind the same epitope of CD86 as 24F because pre-incubation of rat dendritic cells with OX48 antibody did not block binding of PE-conjugated 24F (data not shown). However, OX48 appears to be able to block binding of CD86 with its ligand CD28, as addition of this antibody to T cell cultures led to a similar inhibition of proliferation as 24F [ (23) and data not shown].
CD86 expression does not functionally subdivide CD4 + CD25 + thymocytes in vitro
As CD4 + CD25 + cells in both the thymus and periphery were found to be heterogeneous with regard to CD86 expression, and this marker was virtually absent on CD25 ± cells, it was tested for its utility in functionally subdividing CD25 + cells further with regard to their suppressive activity in vitro. Both CD86 + and CD86 ± subsets of CD4 + CD8 ± CD25 + thymocytes were found to be equally potent in suppressing polyclonal T cell proliferation in vitro (Fig. 5) . CD80 was not used to subdivide CD25 + cells as it was expressed on the majority of these cells.
CD80 and CD86 mRNA is expressed in CD4 + CD25 + T cells
Recently, it has been shown that CD80 expression on T cells in mice and humans not only occurs due to endogenous T cell production of this protein, but also due to its acquisition from APC (42, 43) . To determine whether CD4 + CD25 + T cells were producing endogenous CD80 and CD86, the expression of CD80 and CD86 mRNA was examined. CD25 + and CD25 ± subsets of CD4 + CD8 ± TCRab + thymocytes were sorted to high purity on a MoFlo cell sorter, after initial depletion of CD8-expressing cells. The purity of both sorted populations was >99.9% with regard to TCRab expression, and with regard to CD25 expression the CD25 ± cells were 99.9% pure and the CD25 + cells were >94% pure. Total RNA was puri®ed from these cells, and RT-PCR analysis performed for CD80 and CD86, with b-actin to normalize levels of RNA in the samples. Results shown in Fig. 6 revealed that CD4 + CD25 + thymocytes express mRNA for both CD80 and CD86, indicating that at least part of the observed expression of these molecules is due to endogenous production. As noted for protein expression, there was differential expression of CD80 and CD86 mRNA in CD25 + compared to CD25 ± cells, with barely detectable expression of these transcripts in the CD25 ± subset of mature CD4 + thymocytes.
Discussion
This study describes the further phenotypic characterization of CD4 + CD25 + regulatory T cells in rats and a search for more speci®c markers to distinguish regulatory T cells from conventional T cells. Based on this analysis it was apparent that CD25 + cells in the CD4 + CD8 ± compartment of the thymus have a more mature phenotype than the corresponding CD25 ± cells with respect to expression of Thy1, CD53 and CD44. Thy1 is Con®rmation that OX48 is speci®c for CD86. CD86-transfected p815 cells, and control CD80-transfected or untransfected p815 cells (kindly provided by Hideo Yagita) were stained with OX48 mAb and DAM±PE and analysed on the¯ow cytometer. 24F mAb was a positive control for CD86 expression, 3H5 was a positive control for CD80 expression and OX21 (shown as the un®lled histogram) was used as an isotype control for all three antibodies.
highly expressed on immature thymocytes in rats, expressed in lower levels on recent thymic emigrants and is lost on peripheral T cells within a week of emigration from the thymus (44) . CD25 + cells in the thymus had a mostly Thy1 lo phenotype, distinct from the Thy1 ± phenotype of most mature T cells and the Thy1 hi phenotype of the majority of CD25 ± CD4 + CD8 ± thymocytes. Similarly, CD44 expression and CD53 expression were higher on the majority of CD25 + thymocytes compared with CD25 ± CD4 + CD8 ± thymocytes, corresponding more closely to the levels found on peripheral T cells. Thus, CD25 + thymocytes have a predominantly, but not exclusively, mature phenotype, suggesting that CD25 expression, and perhaps also regulatory function, is acquired relatively late in thymocyte maturation.
In the periphery, CD4 + CD25 + cells were found to have increased expression of CD44, CD48, ICAM, LFA-1, CD200, OX40, CD80 and CD86 compared with CD25 ± cells, consistent with them having a more activated phenotype and in general agreement with previous observations in mice (45) . However, in our search for better markers of regulatory T cell function we focused our functional analyses on those markers that were heterogeneous within the CD25 + population, but were present on only a minority of the CD25 ± subset and did not simply re¯ect different maturational states in the thymus. OX40 and CD86 fell into this category. However, despite the fact that CD4 + CD25 + cells were heterogeneous with respect to OX40 and CD86 in both the thymus and the periphery, this was not found to correlate with heterogeneity in terms of regulatory T cell activity in vitro or in vivo. Thus, CD25 remains for now the most suitable marker available to enrich for T cells with regulatory activity in rats.
Similarly, reports of other attempts to subdivide CD4 + CD25 + T cells in mice have not yet revealed a marker which is more speci®c than CD25 for ex vivo isolated CD4 + T cells with in vitro suppressive activity. In this regard, it has been shown that subdivision of CD4 + CD25 + cells in mice according to expression of CD45RB, CD38, CD62L, CD103 and LAP did not reveal any functional differences in the ability of cells to mediate suppression of T cell proliferation in vitro (46±50), although slight differences in potency were reported for CD103 (49) . In contrast, it has been reported that the ability of CD4 + CD25 + T cells from young NOD mice to delay diabetes in vivo in an adoptive transfer model was found solely in the CD62L high subset, relating probably to differences in the homing properties of the two subsets (51) . Similarly, the ability of whole CD4 + CD8 ± thymocytes to prevent autoimmune diabetes was previously shown to be a property of the CD62L high cell subset in rats (52) and mice (53) .
We noted OX40 expression on a subset of the CD4 + CD45RC low Thy1 ± CD25 ± cells that can also protect against diabetes in our model, but were unable to determine substantial regulatory activity in this subset in vitro or to show that all the in vivo regulatory activity of CD4 + CD25 ± T cells resided exclusively in the OX40 + subset. This contrasts with recent reports of other markers in mice that have been suggested to be useful for the identi®cation of the CD4 + CD25 ± CD45RB low cells with regulatory activity, such as CD103 (49), latency-associated peptide (LAP) (50) and glucocorticoidinduced tumour necrosis factor receptor family-related gene (GITR) (54) . There is evidence to suggest that LAP + cells comprise the major regulatory fraction of CD4 + CD25 ± Fig. 6 . Expression of CD80 and CD86 mRNA in CD4 + CD8-25 + thymocytes. RT-PCR analysis for CD80 and CD86 was performed on RNA puri®ed from CD25 + and CD25 ± subsets of CD4 + CD8 ± TCRab + thymocytes, sorted to high purity on a MoFlo cell sorter as described in the text. b-Actin was used to indicate levels of mRNA in the samples. Control RT ± reactions did not result in the ampli®cation of any DNA, thereby excluding the presence of contaminating genomic DNA in the RNA samples (data not shown). Results are representative of more than three experiments. CD45RB low cells in mice, although in contrast to CD4 + CD25 + cells, CD25 ± LAP + cells lacked in vitro regulatory activity (50) . However, although CD4 + CD25 ± CD103 + cells were found to be regulatory in vivo and to a lesser extent in vitro, the regulatory potential of CD4 + CD103 ± CD45RB low cells was not determined, and therefore it remains unknown whether or not all CD4 + CD25 ± regulatory cells are CD103 + in mice (49) . The same problem applies to the use of GITR as a marker for regulatory CD4 + CD25 ± cells (54) .
Although OX40 and CD86 were not found to be useful as markers for regulatory T cells in rats, these molecules might still be functionally important on regulatory T cells. OX40 is a molecule expressed by T cells after activation, and plays a role in the survival of antigen-experienced T cells and augmentation of immune responses (33) . Attention to date has mainly focused on the role of OX40 on immune effector cells, as injection of agonistic antibodies to OX40 in mice can break peripheral T cell tolerance (55) , and, conversely, neutralizing antibodies against OX40L can be bene®cial in reducing in¯ammatory conditions in mice including colitis (56), experimental autoimmune encephalomyelitis (57) and collageninduced arthritis (58) . However, this study has shown that OX40 is not only expressed on activated effector T cells, but also on many regulatory CD4 + CD25 + T cells in both the thymus and periphery, and in low levels on mature CD4 + CD25 ± thymocytes. Similarly, in humans it has been noted that OX40 expression can be found on scattered medullary thymocytes (59, 60) . This previously unappreciated expression pattern of OX40 should be considered in the interpretation of studies involving therapeutic intervention by targeting of OX40 + T cells and its ligand. Further studies on CD25 + T cells from OX40 ±/± mice will reveal whether OX40 plays any role in regulatory T cell survival or function.
The enrichment of both CD80 and CD86 expression on CD4 + CD25 + T cells in the thymus and periphery has not been reported previously, even in published studies of global mRNA gene expression by CD25 + and CD25 ± CD4 + T cell subsets in mice (12, 48, 61) . The reason for this is not clear, as we have found enrichment for CD80 and CD86 on CD4 + CD25 + cells at both the protein and mRNA level, arguing that their expression on these cells is, at least in part, due to endogenous production and not solely protein acquisition from APC. Further studies will be required to determine the functional signi®cance of CD80/CD86 expression on regulatory CD4 + CD25 + T cells. It remains possible that some of the CD80/CD86 expressed by CD25 + T cells has been acquired from APC and such acquisition could act to limit the availability of co-stimulatory molecules on APC to other T cells at early stages of activation. This notion is consistent with reports that CD80 and CD86 expression is lowered on dendritic cells after interaction with CD25 + cells in vitro (62) , and that in vitro suppression by CD25 + cells can be abrogated if the level of co-stimulation is increased with agonistic CD28 mAb (i.e. suppression only occurs when co-stimulation is limiting). However, it seems implausible that the exclusive action of regulatory CD4 + CD25 + T cells can be via reduction of the costimulatory capacity of APC through CD80/CD86 acquisition because the suppressive activity of CD4 + CD25 + T cells has also been demonstrated in certain APC-free culture systems, e.g. using beads coated with anti-CD3 and anti-CD28 (63).
Nevertheless, it remains possible that CD80/CD86 expression by CD4 + CD25 + T cells could be functionally important in their suppressive activity by providing a ligand for CTLA-4 on other activated T cells or on the regulatory CD4 + CD25 + T cells themselves, which are known to be enriched in the expression of CTLA-4 in mice (5, 8, 64) , humans (34) and now also in rats (41) . In support of this possibility, it was shown by Chai et al. that T cell unresponsiveness induced by presentation of antigen to T cells using co-stimulation-de®cient APC could be abrogated by the addition of antibodies to CD80 or CTLA-4 (65) . As T cells were the only cells expressing CD80 in these experiments, the conclusion was drawn that T cell-expressed CD80 could induce T cell unresponsiveness via ligation of CTLA-4 on neighbouring or even the same T cells. This effect was reported not to occur when co-stimulatory molecules on APC were not limiting, thus showing that increasing costimulation could abrogate the suppressive effect of CD80 expression on T cells, just as it abrogates the suppressive activity of CD4 + CD25 + T cells. These results suggest that one action of regulatory T cells is to limit responses to those cells that are least heavily dependent on co-stimulation. Such an action would be compatible with their involvement in the prevention of autoimmunity, as autoreactive cells are likely to have low-af®nity TCR for self-antigens having avoided negative selection by virtue of this fact. B7-1/B7-2 double-knockout mice were reported to have greatly reduced numbers of CD4 + CD25 + T cells (5) , but the suppressive activity of the remaining cells has not been reported and could provide insight into the possible functional role of B7 expression on CD4 + CD25 + T cells.
In summary, CD4 + CD25 + T cells in rats had enriched, but heterogeneous, expression of OX40 and CD86 in both the thymus and periphery, although these markers were not useful for further subdivision of regulatory activity. It is possible that the expression of these molecules is a re¯ection of the activation state of regulatory T cells rather than a true lineage difference. We noted also that the majority of CD4 + CD25 + cells in rats were distinguished from CD4 + CD25 ± cells by expression of CD80. CD80 therefore joins other molecules that are known to be enriched and relatively homogeneously expressed on CD25 + cells, including CTLA-4 (5, 8, 64) , GITR (48, 66) and, more recently, the transcription factor Foxp3 (67). In addition, CD4 + CD25 + T cells have been reported to be enriched in certain chemokine receptors such as CCR8 (68) and CCR5 (69) . This study also demonstrated 10 differences in the phenotype of rat CD4 + CD25 + cells from peripheral blood compared with spleen and lymph node with regard to any of the antibodies used for screening. 
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